전립선 비대증 외과 치료 시장 규모 : 점유율, 산업 분석 보고서 - 유형별, 최종 사용자별, 지역별 시장 예측(2025-2034년)

The benign prostatic hyperplasia surgical treatment market size is expected to reach USD 3,412.57 million by 2034, according to a new study by Polaris Market Research. The report "Benign Prostatic Hyperplasia Surgical Treatment Market Share, Size, Trends, Industry Analysis Report By Type [Transurethral Resection of the Prostate (TURP), Prostatic Urethral Lift], By End User, By Region; Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Benign prostatic hyperplasia (BPH) surgical treatment refers to medical interventions designed to relieve urinary obstruction caused by an enlarged prostate, typically when medication fails to provide adequate relief. The growing shift toward minimally invasive surgery procedures offers faster recovery and reduced postoperative complications. There is increasing adoption of techniques that minimize tissue damage while ensuring effective symptom management as patients and healthcare providers increasingly favor less invasive options. This trend reflects a broader movement toward patient-centric care and aligns with the global focus on improving procedural outcomes and overall quality of life.

The ongoing integration of advanced surgical technologies across healthcare systems boosts growth opportunities. Innovations such as laser therapies, surgical robots, and improved visualization tools are improving the precision and efficiency of BPH surgeries. These advancements streamline operative workflows and also enable urologists to perform complex procedures with greater consistency and safety. As a result, healthcare providers are better equipped to deliver personalized treatment, reinforcing the evolution toward technologically refined and outcome-driven care models.

Benign Prostatic Hyperplasia (BPH) Surgical Treatment Market Report Highlights

In terms of type, the transurethral resection of the prostate (TURP) segment led the market in 2024, valued at USD 713.43 million, owing to its proven clinical effectiveness and established role as the standard treatment for BPH.

Based on end user, the ambulatory surgery centers (ASCs) segment is expected to record the highest CAGR of 5.7% during the forecast period, driven by increasing demand for outpatient procedures and cost-efficient healthcare delivery.

The North America BPH surgical treatment market accounted for the largest revenue share, and was valued at USD 888.88 million in 2024, attributed to its high BPH prevalence, rapid adoption of advanced surgical methods, and substantial healthcare spending.

Asia Pacific held a 21.61% market share in 2024, supported by rising urological health awareness and expanding investments in healthcare infrastructure.

A few global key players in the benign prostatic hyperplasia surgical treatment market include American Polyfilm, Inc.; BASF; Covestro AG; Novotex Italiana S.p.A.; RTP Company; San Fang Chemical Industry Co., Ltd.; SWM International; The Lubrizol Corporation; Toray Industries, Inc.; and Wiman Corporation.

Polaris Market Research has segmented the benign prostatic hyperplasia surgical treatment market report on the basis of type, end user, and region:

By Type Outlook (Revenue, USD Million, 2020-2034)

Transurethral Resection of Prostate (TURP)

Prostatic Urethral Lift

Water Vapor Therapy

Laser Therapy

Aquablation Therapy

Transurethral Microwave Thermotherapy (TUMT)

Others

By End User Outlook (Revenue, USD Million, 2020-2034)

Hospitals

Ambulatory Surgery Centers and Clinics

Homecare Settings

By Regional Outlook (Revenue, USD Million, 2020-2034)

North America

U.S.

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Rest of Europe

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Vietnam

Australia

Rest of Asia Pacific

Latin America

Argentina

Brazil

Mexico

Rest of Latin America

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa

Rest of Middle East & Africa

Table of Contents

1. Rationale Behind Scope Update for Benign Prostatic Hyperplasia Surgical Treatment Market

2. Global Benign Prostatic Hyperplasia Surgical Treatment Market-Report Overview

• 2.1. Scope of the report
• 2.2. Market Segment Analysis
• 2.3. Regulatory Scenario by Region/Country
• 2.4. Market Investment Scenario Strategic
• 2.5. Market Analysis by Type (USD Million)
  • 2.5.1 Global Benign Prostatic Hyperplasia Surgical Treatment Market by Type (2024-2034)
  • 2.5.2 Transurethral Resection of the Prostate (TURP)
  • 2.5.3 Prostatic Urethral Lift
  • 2.5.4 Water Vapor Therapy
  • 2.5.5 Laser Therapy
  • 2.5.6 Aquablation Therapy
  • 2.5.7 Transurethral Microwave Thermotherapy (TUMT)
  • 2.5.8 Others
• 2.6. Market Analysis by End User (USD Million)
  • 2.6.1 Global Benign Prostatic Hyperplasia Surgical Treatment Market by End User (2024-2034)
  • 2.6.2 Hospitals
  • 2.6.3 Ambulatory Surgery Centers and Clinics
  • 2.6.4 Homecare Settings

3. driver restraint challenge and opportunities of Benign Prostatic Hyperplasia Surgical Treatment Market

• 3.1. Driver, Restraint, Challenge and Opportunities Analysis
  • 3.1.1 Market Driver Analysis
  • 3.1.2 Market Restraint Analysis
  • 3.1.3 Market Opportunity
  • 3.1.4 Market Challenges

4. Global Growth Trends

• 4.1. Industry Trends
  • 4.1.1 SWOT Analysis
    • 4.1.1.1 Strengths
    • 4.1.1.2 Weaknesses
    • 4.1.1.3 Opportunities
    • 4.1.1.4 Threats
  • 4.1.2 PESTEL Analysis
    • 4.1.2.1 Political Landscape
    • 4.1.2.2 Economic Landscape
    • 4.1.2.3 Social Landscape
    • 4.1.2.4 Technological Landscape
    • 4.1.2.5 Environmental Landscape
    • 4.1.2.6 Legal Landscape
  • 4.1.3 Porter's Five Forces Analysis
    • 4.1.3.1 Bargaining Power of Suppliers
    • 4.1.3.2 Bargaining Power of Buyers
    • 4.1.3.3 Threat of Substitute
    • 4.1.3.4 Threat of New Entrant
    • 4.1.3.5 Competitive Rivalry
  • 4.1.4 Value Chain Analysis
  • 4.1.5 Competitive Sales Data Analysis
  • 4.1.6 Estimated Patients Treated, 2024
• 4.2. Potential Market and Growth Potential Analysis

5. Covid-19 Impact

• 5.1. Covid-19 Impact
• 5.2. COVID V, U, W and L Analysis
• 5.3. COVID V Analysis
• 5.4. COVID U Analysis
• 5.5. COVID L Analysis
• 5.6. COVID W Analysis

6. Companies Analysis

• 6.1. M&A and Strategic Activity Analysis in BPH Surgical Treatment Market
• 6.2. Strategy Framework - Global BPH Surgical Treatment Market
• 6.3. Vendor Landscape - Global BPH Surgical Treatment Market
• 6.4. Competitive Environment - Global BPH Surgical Treatment Market

7. Exceutive Summary

8. Global Benign Prostatic Hyperplasia Surgical Treatment MARKET Forecast, 2021-2034, (USD Million)

• 8.1. Global Benign Prostatic Hyperplasia Surgical Treatment Market

9. Global Benign Prostatic Hyperplasia Surgical Treatment Market by Type (2021-2034), (USD Million)

• 9.1. Global Benign Prostatic Hyperplasia Surgical Treatment Market by Type (2021-2027)
• 9.2. Global Benign Prostatic Hyperplasia Surgical Treatment Market by Type (2028-2034)

10. Global Benign Prostatic Hyperplasia Surgical Treatment Market by End User (2021-2034), (USD Million)

• 10.1. Global Benign Prostatic Hyperplasia Surgical Treatment Market by End User (2021-2027)
• 10.2. Global Benign Prostatic Hyperplasia Surgical Treatment Market by End User (2028-2034)

11. Global Benign Prostatic Hyperplasia Surgical Treatment Market by REGION (2021-2034), (USD Million)

• 11.1. Global Benign Prostatic Hyperplasia Surgical Treatment Market by Region (2021-2027)
• 11.2. Global Benign Prostatic Hyperplasia Surgical Treatment Market by Region (2028-2034)

12. North America Benign Prostatic Hyperplasia Surgical Treatment by COUNTRIES (2021-2034), (USD Million)

• 12.1. North America Benign Prostatic Hyperplasia Surgical Treatment by Countries (2021-2027)
• 12.2. North America Benign Prostatic Hyperplasia Surgical Treatment by Countries (2028-2034)

13. North America Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

• 13.1. North America Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
• 13.2. North America Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

14. North America Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

• 14.1. North America Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
• 14.2. North America Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

15. United States Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

• 15.1. United States Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
• 15.2. United States Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

16. United States Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

• 16.1. United States Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
• 16.2. United States Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

17. Canada Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

• 17.1. Canada Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
• 17.2. Canada Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

18. Canada Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

• 18.1. Canada Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
• 18.2. Canada Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

19. Mexico Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

• 19.1. Mexico Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
• 19.2. Mexico Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

20. Mexico Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

• 20.1. Mexico Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
• 20.2. Mexico Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

21. Europe Benign Prostatic Hyperplasia Surgical Treatment by Countries (2021-2034), (USD Million)

• 21.1. Europe Benign Prostatic Hyperplasia Surgical Treatment by Countries (2021-2027)
• 21.2. Europe Benign Prostatic Hyperplasia Surgical Treatment by Countries (2028-2034)

22. Europe Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

• 22.1. Europe Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
• 22.2. Europe Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

23. Europe Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

• 23.1. Europe Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
• 23.2. Europe Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

24. Germany Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

• 24.1. Germany Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
• 24.2. Germany Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

25. Germany Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

• 25.1. Germany Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
• 25.2. Germany Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

26. UK Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

• 26.1. UK Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
• 26.2. UK Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

27. UK Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

• 27.1. UK Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
• 27.2. UK Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

28. France Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

• 28.1. France Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
• 28.2. France Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

29. France Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

• 29.1. France Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
• 29.2. France Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

30. Italy Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

• 30.1. Italy Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
• 30.2. Italy Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

31. Italy Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

• 31.1. Italy Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
• 31.2. Italy Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

32. Spain Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

• 32.1. Spain Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
• 32.2. Spain Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

33. Spain Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

• 33.1. Spain Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
• 33.2. Spain Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

34. Switzerland Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

• 34.1. Switzerland Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
• 34.2. Switzerland Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

35. Switzerland Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

• 35.1. Switzerland Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
• 35.2. Switzerland Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

36. Netherland Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

• 36.1. Netherland Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
• 36.2. Netherland Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

37. Netherland Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

• 37.1. Netherland Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
• 37.2. Netherland Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

38. Rest of Europe Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

• 38.1. Rest of Europe Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
• 38.2. Rest of Europe Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

39. Rest of Europe Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

• 39.1. Rest of Europe Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
• 39.2. Rest of Europe Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

40. Asia Pacific Benign Prostatic Hyperplasia Surgical Treatment by COUNTRIES (2021-2034), (USD Million)

• 40.1. Asia Pacific Benign Prostatic Hyperplasia Surgical Treatment by Countries (2021-2027)
• 40.2. Asia Pacific Benign Prostatic Hyperplasia Surgical Treatment by Countries (2028-2034)

41. Asia Pacific Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

• 41.1. Asia Pacific Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
• 41.2. Asia Pacific Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

42. Asia Pacific Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

• 42.1. Asia Pacific Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
• 42.2. Asia Pacific Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

43. China Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

• 43.1. China Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
• 43.2. China Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

44. China Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

• 44.1. China Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
• 44.2. China Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

45. Japan Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

• 45.1. Japan Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
• 45.2. Japan Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

46. Japan Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

• 46.1. Japan Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
• 46.2. Japan Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

47. India Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

• 47.1. India Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
• 47.2. India Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

48. India Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

• 48.1. India Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
• 48.2. India Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

49. South Korea Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

• 49.1. South Korea Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
• 49.2. South Korea Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

50. South Korea Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

• 50.1. South Korea Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
• 50.2. South Korea Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

51. Australia Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

• 51.1. Australia Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
• 51.2. Australia Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

52. Australia Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

• 52.1. Australia Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
• 52.2. Australia Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

53. Malaysia Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

• 53.1. Malaysia Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
• 53.2. Malaysia Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

54. Malaysia Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

• 54.1. Malaysia Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
• 54.2. Malaysia Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

55. Indonesia Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

• 55.1. Indonesia Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
• 55.2. Indonesia Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

56. Indonesia Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

• 56.1. Indonesia Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
• 56.2. Indonesia Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

57. Rest of Asia Pacific Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

• 57.1. Rest of Asia Pacific Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
• 57.2. Rest of Asia Pacific Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

58. Rest of Asia Pacific Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

• 58.1. Rest of Asia Pacific Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
• 58.2. Rest of Asia Pacific Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

59. Middle East & Africa Benign Prostatic Hyperplasia Surgical Treatment by COUNTRIES (2021-2034), (USD Million)

• 59.1. Middle East & Africa Benign Prostatic Hyperplasia Surgical Treatment by Countries (2021-2027)
• 59.2. Middle East & Africa Benign Prostatic Hyperplasia Surgical Treatment by Countries (2028-2034)

60. Middle East & Africa Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

• 60.1. Middle East & Africa Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
• 60.2. Middle East & Africa Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

61. Middle East & Africa Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

• 61.1. Middle East & Africa Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
• 61.2. Middle East & Africa Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

62. Saudi Arabia Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

• 62.1. Saudi Arabia Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
• 62.2. Saudi Arabia Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

63. Saudi Arabia Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

• 63.1. Saudi Arabia Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
• 63.2. Saudi Arabia Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

64. UAE Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

• 64.1. UAE Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
• 64.2. UAE Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

65. UAE Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

• 65.1. UAE Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
• 65.2. UAE Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

66. South Africa Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

• 66.1. South Africa Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
• 66.2. South Africa Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

67. South Africa Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

• 67.1. South Africa Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
• 67.2. South Africa Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

68. Rest of Middle East & Africa Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

• 68.1. Rest of Middle East & Africa Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
• 68.2. Rest of Middle East & Africa Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

69. Rest of Middle East & Africa Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

• 69.1. Rest of Middle East & Africa Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
• 69.2. Rest of Middle East & Africa Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

70. Latin America Benign Prostatic Hyperplasia Surgical Treatment by COUNTRIES (2021-2034), (USD Million)

• 70.1. Latin America Benign Prostatic Hyperplasia Surgical Treatment by Countries (2021-2027)
• 70.2. Latin America Benign Prostatic Hyperplasia Surgical Treatment by Countries (2028-2034)

71. Latin America Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

• 71.1. Latin America Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
• 71.2. Latin America Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

72. Latin America Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

• 72.1. Latin America Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
• 72.2. Latin America Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

73. Brazil Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

• 73.1. Brazil Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
• 73.2. Brazil Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

74. Brazil Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

• 74.1. Brazil Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
• 74.2. Brazil Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

75. Argentina Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

• 75.1. Argentina Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
• 75.2. Argentina Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

76. Argentina Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

• 76.1. Argentina Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
• 76.2. Argentina Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

77. Rest of Latin America Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

• 77.1. Rest of Latin America Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
• 77.2. Rest of Latin America Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

78. Rest of Latin America Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

• 78.1. Rest of Latin America Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
• 78.2. Rest of Latin America Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

79. Company Profiles

• 79.1. Alembic Pharmaceuticals Limited.
  • 79.1.1 Company Details
  • 79.1.2 Financial (USD Million)
  • 79.1.3 Product Summary
  • 79.1.4 Recent Developments
• 79.2. Boston Scientific Corporation
  • 79.2.1 Company Details
  • 79.2.2 Financial (USD Million)
  • 79.2.3 Product Summary
  • 79.2.4 Recent Developments
• 79.3. Asahi Kasei Corporation
  • 79.3.1 Company Details
  • 79.3.2 Asahi Kasei Financials (USD Million)
  • 79.3.3 Product Summary
• 79.4. Coloplast Group
  • 79.4.1 Company Details
  • 79.4.2 Financial (USD Million)
  • 79.4.3 Product Summary
• 79.5. Cook Medical
  • 79.5.1 Company Details
  • 79.5.2 Financial (USD Million)
  • 79.5.3 Product Summary
  • 79.5.4 Recent Developments
• 79.6. Medifocus, Inc.
  • 79.6.1 Company Details
  • 79.6.2 Financial (USD Million)
  • 79.6.3 Product Summary
  • 79.6.4 Recent Developments
• 79.7. Karl Storz Se & Co. KG
  • 79.7.1 Company Details
  • 79.7.2 Financial (USD Million)
  • 79.7.3 Product Summary
• 79.8. Olympus Corporation
  • 79.8.1 Company Details
  • 79.8.2 Financial (USD Million)
  • 79.8.3 Product Summary
  • 79.8.4 Recent Developments
• 79.9. Medtronic
  • 79.9.1 Company Details
  • 79.9.2 Financial (USD Million)
  • 79.9.3 Product Summary
• 79.10. The Johns Hopkins Hospital
  • 79.10.1 Company Details
  • 79.10.2 Financial (USD Million)
  • 79.10.3 Product Summary
  • 79.10.4 Recent Developments
• 79.11. Cleveland Clinic
  • 79.11.1 Company Details
  • 79.11.2 Financial (USD Million)
  • 79.11.3 Product Summary
  • 79.11.4 Recent Developments

80. Conclusion

81. Reference Link

82. Analyst suggestions and recommendations

83. Appendix

• 83.1. Methodology
• 83.2. Research Data Source
  • 83.2.1 Secondary Data
  • 83.2.2 Key Data from Secondary
  • 83.2.3 Primary Data
  • 83.2.4 Key Data from Primary
  • 83.2.5 Industry Insight from Professional Leaders
  • 83.2.6 Market Estimation
  • 83.2.7 Market Estimation: Top-down and Bottom-up Approach
  • 83.2.8 Legal Disclaimer

84. Research Scope